Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Recruiting · NCT05489887 · Registry updated 2026-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-08-12 | NCT05489887 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Giselle Sholler | 7 |
| Y-mAbs Therapeutics | 12 |
26 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.